GlobalData has reviewed the growth of global clinical trials in the immuno-oncology (IO) space that were initiated between 2008 and 2017. IO trials were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center using an ‘immuno-oncology’ filter based on drugs tagging.
Immuno-oncology therapies are separated into four broad segments:
Go deeper with GlobalData
- Adoptive cellular therapy, which includes chimeric antigen receptor T-cell immunotherapy (CAR-T), cytotoxic T lymphocyte immunotherapy (CTL), natural killer cell immunotherapy (NKT), regulatory T cells (Treg), and tumor-infiltrating lymphocyte immunotherapy (TIL).
- Immune checkpoint modulators.
- Immune system modulators, which include various cancer vaccines.
- Immunomodulatory enzyme inhibitors.
The highest growth was attributed to immune checkpoint modulators, where the number of trials increased at a much higher rate than the other IO segments, concurrent with the surge in investigations into PD-1 targets (see Figure 1).
Figure 1: global IO clinical trials, N, by segment
Source: GlobalData. © GlobalData
Related Reports
GlobalData (2017). PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities, August 2017, Report Code: GDHC009PFR.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataFor more insight and data, visit the GlobalData Report Store – Drug Development Technology is part of GlobalData Plc.
